【TMCLIFE 0101 交流专区】TMC生命科学

williamnkk81

icy97 发表于 27-9-2012 09:58 AM
@williamnkk81
这就不晓得了。。
这问题就有劳william兄帮你解答，因他可能会较清楚。。

哈哈。。好的。。。

williamnkk81

missemma86 发表于 27-9-2012 10:10 AM
请问你是做哪行的呢。。？
genting sp适合进吗。。？
tmc。。？

我是股票经纪/交易员/私人投资顾问。。。

genting sg 最好不要。。。可以看 genting M..
tmclife 。。。 公司不会被私有的在目前的情况。。。公司有新的大股东了。。 医药业务有发展。。。要等。和这家公司有些小。。很难跟KPJ。。IHH比较。。。
supermax...机会来的可以买来收。。。

icy97

missemma86 发表于 27-9-2012 10:10 AM
请问你是做哪行的呢。。？
genting sp适合进吗。。？
tmc。。？

如你接下来还有别的疑问，可光临william兄的个人专区询问。。这里就专注于有关TMCLIFE，0101的交流。。
谢合作。。

missemma86

williamnkk81 发表于 27-9-2012 10:22 AM
我是股票经纪/交易员/私人投资顾问。。。

genting sg 最好不要。。。可以看 genting M..

那么你是跑kl的？
supermx什么价位可以买。。。？
mrcb你意见如何。。。？
现在tmc可以买来收吗。。？那个大客是peter lim...??

williamnkk81

missemma86 发表于 27-9-2012 07:56 PM
那么你是跑kl的？
supermx什么价位可以买。。。？
mrcb你意见如何。。。？

那么你是跑kl的？主要是在KL。。。但我的客户分布全马。。和国外。。
supermx什么价位可以买。。。？现在都可以的。。但有起了一些。。。
mrcb你意见如何。。。？这个很怪的公司。。。要看EPF的。。。公司是有些炒作的。。。
现在tmc可以买来收吗。。？如果要那要长期。。因为公司还不稳定。。那个大客是peter lim...??哈哈。。他。。还没有资格成为我的顾客。。我和他不是很同路。。。

你有什么问题可以PM我还是我的专区。。。版主警告了。。。

icy97

TMC生科全年未轉盈

投資致富  2012-10-15 11:45

MR Yeoh問：
TMC生命科學（TMCLIFE，0101，主板貿服組）是丹斯里陳志遠的公司，為甚麼一直沒有動靜？請問應該持有嗎？這間公司前景又如何？

答：
根據TMC生命科學的2012年報，丹斯里陳志遠仍是公司大股東。

截至2012年5月31日止第四季，該公司轉虧為盈，取得淨利12萬2千令吉，前期為淨虧損233萬令吉；而營業額則增加至1千911萬5千令吉，前期為1千655萬8千令吉。

全年仍蒙受淨虧損648萬3千令吉，前期為淨虧損3千501萬4千令吉，而全年營業額則減少至6千198萬1千令吉，前期為7千864萬3千令吉。每股資產值為17仙。

該公司管理層在去年11月的股東大會後表示，計劃在2012年撥出1千萬令吉充當資本開銷，強化醫藥器材設備等，及努力吸引國內外客戶以提昇醫療中心的使用率，以協助公司轉虧為盈。

該公司最新的企業活動，為今年8月初宣佈以1千360萬令吉脫售公司的兩項資產，充當營運資金及償還銀行貸款。它以260萬令吉脫售檳城麗陽醫療中心的100%股權，以及以1千100萬令吉脫售有關醫療建築及地庫。

該公司前景，將與其在私人醫院或醫療中心領域的競爭力而定，該行業雖然具抗禦特質，不過競爭激烈。該公司預期2013財政年業績表現會改善。上述資料僅供參考。（星洲日報／投資致富‧投資問診室）

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31/08/2012

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31/08/2012	31/08/2011	31/08/2012	31/08/2011
		$$'000	$$'000	$$'000	$$'000

1	Revenue	16,402	12,492	16,402	12,492
2	Profit/(loss) before tax	148	-1,836	148	-1,836
3	Profit/(loss) for the period	114	-1,836	114	-1,836
4	Profit/(loss) attributable to ordinary equity holders of the parent	2,787	-2,334	2,787	-2,334
5	Basic earnings/(loss) per share (Subunit)	0.38	-0.39	0.38	-0.39
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.1500		0.1500

Remarks :

The unaudited condensed consolidated statement of profit or loss and other comprehensive income should be read in conjuction with the audited financial statements for the financial year ended 31 May 2012 and the accompanying explanatory notes attached to the interim financial statements.

TMC轉虧為盈 首季淨利279萬

企業財經15/10/2012 22:00
（吉隆坡15日訊）將醫藥旅遊業務成為主要營業額來源之一的TMC（TMCLIFE，0101，主要板貿易）第1季淨利獲翻倍成長，取得279萬令吉，亮眼成績。

該公司今日向馬證交所報備指出，截至8月31日財年第1季淨利揚2倍至278萬7000令吉，去年同期為虧損233萬4000令吉。

TMC首季營業額上漲31%至1640萬2000令吉，稅前盈利為14萬8000令吉，去年同期為虧損183萬6000令吉；每股盈利報0.38仙。

自TMC將醫藥旅遊業務成為該公司主要營業額來源之一后，該決定有助將公司淨利轉虧為盈，並獲雙倍成長，取得亮眼成績。

該公司指出，該公司未來將著重將醫藥旅遊業務擴大，邁向國際市場，並增加專業醫學顧問的數量。

該公司董事樂觀認為，配合醫藥旅遊業務營銷活動，該公司業績可持續亮眼的表現，取得好成績。[ChinaPress]

icy97

icy97 发表于 10-8-2012 06:38 PM
生命科学260 万售槟城TMC

财经新闻 财经  2012-08-10 13:58

TMC LIFE SCIENCES BERHAD

Type	Announcement
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) NON RELATED PARTY TRANSACTIONS
Description	TMC LIFE SCIENCES BERHAD (“TMC”) I.        DISPOSAL OF SHARES IN TROPICANA MEDICAL CENTRE (PENANG) SDN. BHD. BY TMC AND ITS WHOLLY-OWNED SUBSIDIARY, TMC WOMEN’S SPECIALIST HOLDINGS SDN. BHD. TO CARL CORRYNTAN HOLDINGS SDN. BHD. (“PURCHASER”) FOR CASH CONSIDERATION OF RM2,600,000. II.        DISPOSAL OF PROPERTY BY TMC PROPERTIES SDN. BHD., A WHOLLY OWNED SUBSIDIARY OF TMC TO THE PURCHASER FOR A CASH CONSIDERATION OF RM11,000,000. [COLLECTIVELY “DISPOSALS”]
Unless otherwise stated, definitions used in this announcement shall carry the same meanings as those defined in the earlier announcement dated 8 August 2012. We refer to the previous announcements and reply to query by the Company on 8 August 2012, 10 August 2012, 13 August 2012 and 1 November 2012 in relation to the Disposals. The Board of Directors of TMC wishes to announce that the Company had acceded to the Purchaser’s request of 29 November 2012 that the Purchaser be allowed to make payment of the Amount Owing to Related Parties of RM2,400,000 (which amount is to be settled by the Purchaser at least 7 days before the Completion Date by virtue of the Share SPA) on 7 December 2012, provided that all other payments  i.e. the Share Balance Sum and Property Balance Sum, to be paid on the Completion Date pursuant to Share SPA and Property SPA, are also settled on the 7 December 2012.   There is no change to the Completion Date which is on 8 December 2012.

icy97

TMC LIFE SCIENCES BERHAD

Type	Announcement
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) NON RELATED PARTY TRANSACTIONS
Description	TMC LIFE SCIENCES BERHAD (“TMC”) I.        DISPOSAL OF SHARES IN TROPICANA MEDICAL CENTRE (PENANG) SDN. BHD. BY TMC AND ITS WHOLLY-OWNED SUBSIDIARY, TMC WOMEN’S SPECIALIST HOLDINGS SDN. BHD. TO CARL CORRYNTAN HOLDINGS SDN. BHD. (“PURCHASER”) FOR CASH CONSIDERATION OF RM2,600,000. II.        DISPOSAL OF PROPERTY BY TMC PROPERTIES SDN. BHD., A WHOLLY OWNED SUBSIDIARY OF TMC TO THE PURCHASER FOR A CASH CONSIDERATION OF RM11,000,000. [COLLECTIVELY “DISPOSALS”]
Unless otherwise stated, definitions used in this announcement shall carry the same meanings as those defined in the earlier announcement dated 8 August 2012. We refer to the previous announcements and reply to query by the Company on 8 August 2012, 10 August 2012, 13 August 2012, 1 November 2012 and 29 November 2012 in relation to the Disposals. The Board of Directors of TMC Life Sciences Berhad (“TMC”) wishes to announce that the Disposals has been completed today with the receipt of the payment of the Amount Owing to Related Parties of RM2,400,000, the Share Balance Sum of RM1,989,589.93 (after deducting the amount of RM350,410.07 being the deduction for the increase in the net liabilities of TMCP between 31 July 2012 and the Share Completion Date pursuant to the Share SPA) and Property Balance Sum of RM9,900,000.00. Following the said completion, TMCP ceased to be a subsidiary of TMC and TMC Prop ceased to be the owner of the Property, subject to the completion of registration of the transfer of the land title of the Property into the name of the Purchaser.

icy97

陈志远增持TMC生科至31.06%

财经新闻 财经  2012-12-14 10:35
（吉隆坡13日讯）丹斯里陈志远透过成功机构（BjCorp，3395，主板贸服股）增持TMC生命科学（TMCLife，0101，主板贸服股）股权，从30.78%提升至31.06%。

根据马交所资料，上述增持动作皆透过公开市场完成。

目前，成功机构的持股权已逼近TMC生命科学单一最大股东--新加坡富豪林荣富的32.59%股权。

换言之，这两大股东就已经掌控了公司63.65%的股权。

由于单一集团或个人持股达33%将触动强制性全面献购（MGO）水平，因此业界观察员怀疑、可能会有相关的举动在进行着。

值得注意的是，这两位马新富豪也同为新加坡英华美教育集团（Informatics Education）的大股东。

根据彭博社数据，成功机构和林荣富分别在英华美教育集团持有27.15%与20.77%。

TMC生命科学最新业绩显示，截至2012年8月31日财年首季，营业额按年涨31%报1640万令吉，上财年同期为1240万令吉，归功于增加病床后的高病人运转率。

净利方面，则转亏为盈至278万令吉，上财年同期为净亏损233万令吉。[Nanyang]

missemma86

@Vincent1818
TMC是时候买进了吗。。？

Vincent1818

missemma86 发表于 14-12-2012 10:00 PM
@Vincent1818
TMC是时候买进了吗。。？

这家公司是很小的，还是净亏损，长期收益是很不确定的。

如果你是从短期来看，那还可以跟随他们的炒作。。。不过如果你是新人，最好不要。。。

missemma86

Vincent1818 发表于 15-12-2012 07:59 AM
这家公司是很小的，还是净亏损，长期收益是很不确定的。

如果你是从短期来看，那还可以跟随他们的炒作 ...

bjcorp你觉得如何。。。？？

icy97

TMC 生命科学转盈

财经新闻 财经  2013-01-22 10:54
（吉隆坡21日讯）TMC生命科学（TMCLife，0101，主板贸服股）截至2012年11月30日次季转亏为盈，录得453万7000令吉净利。

相较之下，公司上财年同期净亏达303万7000令吉。

TMC生命科学次季营业额从上财年同期的1375万4000令吉，上涨27.36%至1751万7000令吉。

营业额上涨主要是因为本地和国外的病人增加，医药中心病床和所提供的专科也增加。

累积现财年上半年，公司也转亏为盈净赚99万3000令吉。上财年同期则净亏537万1000令吉。

累积首6个月，TMC生命科学营业额涨29.23%，报3391万9000令吉。上财年同期为2624万6000令吉。

现财年次季每股盈利为0.57仙，上财年同期每股亏损达0.5仙。现财年首半年每股盈利为0.93仙，上财年同期每股亏损达0.89仙。[南洋商报财经]

SUMMARY OF KEY FINANCIAL INFORMATION 30/11/2012

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30/11/2012	30/11/2011	30/11/2012	30/11/2011
		$$'000	$$'000	$$'000	$$'000

1	Revenue	17,517	13,754	33,919	26,246
2	Profit/(loss) before tax	827	-2,529	975	-4,365
3	Profit/(loss) for the period	879	-2,488	993	-4,324
4	Profit/(loss) attributable to ordinary equity holders of the parent	4,537	-3,037	7,324	-5,371
5	Basic earnings/(loss) per share (Subunit)	0.57	-0.50	0.93	-0.89
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.1600		0.1500

icy97

传柔特区医院注入TMC生科

财经新闻 财经  2013-01-27 08:44
（吉隆坡26日讯）TMC生命科学（TMCLife，0101，主板贸服股）准备把另一家医院纳入旗下，这次是在柔佛发展蓬勃的马来西亚依斯干达特区的医疗枢纽。

知情人士告诉《The Edge》财经周刊：“TMC生命科学单一大股东———新加坡亿万富豪林荣富，计划把1座拥有200个床位及正在兴建的医疗枢纽，纳入该公司的管理，此举将显著扩充该公司在国内的发展。”

他披露，目前尚不清楚TMC生命科学会否持有部分股权。

上述医疗枢纽价值2亿新元（约4.9亿令吉），旨在提供便宜但优质医疗服务。

依斯干达特区的主要海滨地段面积为24.7英亩，上述医疗枢纽是该发展计划的一部分。

传汤姆森负责管理

依斯干达特区发展项目，包括滨海城市与综合建筑物，涵盖医院、公寓、娱乐场所及购物中心，整个发展项目预计耗资10亿至20亿新元（约24亿至49亿令吉）。

上述医院预料会在2015年竣工，将成为推动医疗枢纽增长的催化剂。

目前，市场传言新加坡汤姆森医疗私人有限公司的咨询与管理臂膀———汤姆森国际健康服务，将负责管理上述医院。

林荣富在2010年私有化新加坡汤姆森医疗私人有限公司。

除了林荣富（持股权32.59%）之外，TMC生命科学其他大股东，包括我国企业大亨丹斯里陈志远。

从去年5月起，陈志远通过成功机构（BjCorp，3395，主板贸服股），收购TMC生命科学的1587万股，或1.98%股权。

随后，他逐渐累积持股，目前他已持有TMC生命科学的32.27%股权，成为该公司的第二大股东。[南洋商报财经]

icy97

傳大股東欲注入資產 TMC不知情股價跌1仙

財經股市30/01/2013 22:00
（吉隆坡30日訊）TMC（TMCLIFE，0101，主要板貿易）說，對于大股東新加坡億萬富翁林榮福，欲在大馬依斯干達（Iskandar Malaysia）開設醫療中心傳聞不知情。

該公司今日馬證交所澄清，指在咨詢董事與大股東后，對財經週刊《The Edge》報導上述事宜並不知情，董事局至今並未接獲林榮福通知，欲將依斯干達醫療中心注入TMC名下。

文告說，若有任何相關進展，TMC將再行向馬證交所匯報。

開設內有200張床醫院

財經週刊《The Edge》引述業界人士報導，林榮福將在依斯干達開設內有200張床的醫院，這項舉措能顯著擴張TMC業務，但現在仍不確定TMC是否持有這家醫院。

報導說，擁有這家位于新山海關和新加坡兀蘭關卡醫療中心的股權及運營權，能大力推動TMC成長，以彌補去年脫售檳城麗陽醫院帶來的虧損。

另廂，TMC全日窄幅波動，早盤微起0.5仙至38.5仙，休市時跌0.5仙掛37.5仙，交投略顯淡靜，午盤間走勢靠軟，閉市報37仙，跌1仙，成交量156萬8900股。[中国报财经]

TMC LIFE SCIENCES BERHAD

Type	Announcement
Subject	OTHERS
Description	Clarification on the news article published in the Edge Malaysia on 28 January 2013 entitled “Lim to inject Iskandar hospital into TMC Life
Reference is made to the news article published in the Edge Malaysia on 28 January 2013 entitled “Lim to inject Iskandar hospital into TMC Life”, in particular, the following statements:- “Industry executives says TMC’s single largest shareholder, Singapore billionaire Peter Lim, is looking at putting under TMC’s management a 200-bed hospital that is being constructed in the hub – a move that will significantly expand the company’s reach in the country.” “The executives say it is uncertain at this juncture if TMC will own part of the S$200 million hospital that is being positioned as a provider of cheaper but high-quality medical care in the region.” The Board of Directors of TMC Life Sciences Berhad (“TMC Life”) has made due enquiry with its Directors and major shareholder over the above statements and wishes to clarify that the major shareholder was not aware of the above statements as reported in the Edge Malaysia and the Board did not receive any notification on its major shareholder’s plan of injecting the Iskandar hospital into TMC Life. The Company will make the necessary announcement to Bursa Malaysia Securities Berhad should there be any material information that falls under the ambit of the Main Market Listing Requirements.

icy97

TMC LIFE SCIENCES BERHAD

Type	Announcement
Subject	OTHERS
Description	Clarification on the news articles published in the Edge Malaysia on 28 January 2013 entitled “Lim to inject Iskandar hospital into TMC Life”
Reference is made to the announcement made by the Company on 30 January 2013 in relation to the clarification on the news article published in the Edge Malaysia on 28 January 2013 entitled “Lim to inject Iskandar hospital into TMC Life”. The Board of Directors of TMC Life Sciences Berhad (“TMC Life”) wishes to further clarify that the Board is not aware of nor did it receive any offer to manage the 200-bed hospital as mentioned in the article.

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 28/02/2013

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		28/02/2013	29/02/2012	28/02/2013	29/02/2012
		$$'000	$$'000	$$'000	$$'000

1	Revenue	17,733	14,557	51,652	40,803
2	Profit/(loss) before tax	278	-847	1,253	-4,955
3	Profit/(loss) for the period	261	-917	1,254	-4,983
4	Profit/(loss) attributable to ordinary equity holders of the parent	2,834	-1,234	10,158	-6,605
5	Basic earnings/(loss) per share (Subunit)	0.35	-0.19	1.27	-1.03
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.1600		0.1500

icy97

TMC LIFE SCIENCES BERHAD

Type	Announcement
Subject	OTHERS
Description	Extension of time for the utilisation of proceeds raised from the renounceable rights issue.
Following the update on the utilisation of right issue proceeds included in the quarterly financial result announcement dated 22 April 2013, the Board of Directors of TMC Life Sciences Berhad wishes to extend the timeframe for the utilisation of proceeds raised from the renounceable right issue which was completed on 22 December 2011.

Attachments Extension of time for utilisation of proceeds from rights issue.pdf

Type	Announcement
Subject	OTHERS
Description	Clarification to the announcement in relation to the extension of time for the utilisation of proceeds raised from the renounceable rights issue.
We refer to the announcement dated 22 April 2013 and wish to clarify as follows:- The fertility centre in Kuantan, which is one of the six (6) fertility centres as mentioned in above statement contained in the Abridged Prospectus, had ceased operation since June 2012 due to its continuing losses over the years. In August 2012, the Company had disposed of its hospital in Penang (with the exception of the fertility centre in Penang). Hence the expansion and renovation at the hospital in Penang was not carried out as planned. Consequent to the disposal of the hospital in Penang, the fertility centre in the said hospital is in the midst of relocating from the hospital to a new site at Straits Quay, Penang. The said centre is expected to commence its operation upon completion of the required renovation and after all necessary authorities approvals have been obtained which is anticipated to be within 4 months from the date hereof. In addition, renovation to the other fertility centres was also delayed due to constraint in manpower resources. As for the hospital at Kota Damansara, the purchase of certain medical equipment and renovation of new consultant suites were timed to be in line with recruitment of new consultants who will commence their respective practices at varying times during the course of the next financial year.

icy97

http://biz.sinchew.com.my/node/78553
投資致富  2013-07-14 19:22

黃先生問：
TMC生命科學（TMCLIFE，0101，主板貿服組）的大股東是陳志遠嗎？這家公司涉及甚麼業務？手持甚麼工程？這幾年業績如何？

答：

TMC科學
陳志遠為大股東

談到TMC科學，丹斯里陳志遠通過旗下多家公司非直接持有TMC科學的30.49%股權，為大股東之一，而新加坡億萬富翁林榮福則非直接持有32.59%股權。

TMC科學涉及保健業務，麗陽保健中心是旗下主要醫院，雖然因新建設醫院減值而導致早前蒙虧，惟截至2013年2月28日止，首9個月成功轉虧為盈錄得1千零15萬8千令吉，相比前期蒙受660萬5千令吉淨虧損。

該公司的資產負債表強穩，手持1千720萬令吉現金，且25倍本益比仍比區域保健業者估值折價。

在新大股東及管理層崛起後，TMC科學的營運出現正面改變，包括更好的成本管理、償還債務及脫售非核心和低回酬資產，並專注在醫院的營運上。
同時，最近業績改善顯示行銷策略奏效，成功吸引海內外的更多病人前來就醫，有助抑制進一步虧損。

分析員預計該公司可在本財政年轉虧為盈，因為旗下醫院服務虧損料收窄、婦產科業務有利可圖、融資成本低企，加上去年脫售兩項資產而取得賺益。

分析員相信因營運成本高企而引發的最壞時期已過去，因而維持其“買進”評級，合理價訂在50仙。（星洲日報／投資致富‧投資問診室）